Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial
Publication date: Available online 5 October 2026 Source: European Urology Oncology Author(s): Niven Mehra, Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, Neal Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Emma Brown, Jae Young Joung, Mikio Sugimoto, Young Deuk Choi, Daniel Castellano, Yüksel Ürün, Christian Hosius, David McGuinness, Arnold Degboe, Fred Saad
Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126002476?dgcid=rss_sd_all
Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126002476?dgcid=rss_sd_all
“Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial.” European Urology Oncology.
@article{article45682,
title = {Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126002476?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...